Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 9:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 742 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Alcohol (Oral) Clear all
Completed Phase 2Phase 3 Interventional Results available

26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00463567
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
Interventions
Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.), Placebo to Indacaterol, Placebo to Formoterol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
2,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
221
States / cities
Anniston, Alabama • Birmingham, Alabama • Homewood, Alabama + 163 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

NCT01970501
View directory record Official record
Conditions
Current or Recent History of Atrial Fibrillation
Interventions
bucindolol hydrochloride, metoprolol succinate, Placebo oral capsule
Drug · Other
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
48
States / cities
Anchorage, Alaska • Phoenix, Arizona • East Palo Alto, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 6, 2026, 9:42 PM EDT
Not yet recruiting Phase 1 Interventional

Safety and Tolerability of NTR-101 in Patients With Acute Alcohol-Associated Hepatitis

NCT06750588
View directory record Official record
Conditions
Alcohol-Associated Hepatitis
Interventions
bacteriophage preparation
Drug
Lead sponsor
Nterica Bio inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Coronado, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

Personalized Treatment Algorithms for Difficult-to-treat Asthma

NCT04179461
View directory record Official record
Conditions
Asthma in Children
Interventions
Cholecalciferol, antihistamine, Azithromycin, emollient cream, Fluticasone Propionate, Asthma Controller Medication
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

NCT00783705
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Squamous Lung Dysplasia
Interventions
placebo, inositol
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
45 Years to 79 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
3
States / cities
Scottsdale, Arizona • Rochester, Minnesota • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 4 Interventional Results available

Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients

NCT00744237
View directory record Official record
Conditions
Hypertension, Type 2 Diabetes Mellitus
Interventions
Nebivolol, Metoprolol ER, HCTZ
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 85 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
62
States / cities
Athens, Alabama • Huntsville, Alabama • Bell Gardens, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2011 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy

NCT01056341
View directory record Official record
Conditions
Infantile Hemangioma
Interventions
Propranolol, Placebo
Drug
Lead sponsor
Pierre Fabre Dermatology
Industry
Eligibility
35 Days to 150 Days
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Irvine, California • Redwood City, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 6, 2026, 9:42 PM EDT
Not yet recruiting Phase 2 Interventional

Combination Therapy for Alcohol Use Disorder

NCT07249554
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Placebo, Glucagon-Like Peptide-1 Agonist (GLP-1), Naltrexone (oral tablets)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Havre de Grace, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis

NCT01048866
View directory record Official record
Conditions
Pharyngitis
Interventions
placebo, flurbiprofen, acetaminophen 650mg
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Response to Anti-hypertensives in Pregnant and Postpartum Patients

NCT03506724
View directory record Official record
Conditions
Hypertension in Pregnancy, Preeclampsia
Interventions
Nifedipine, Labetalol
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery

NCT00953212
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
beta blockers, amiodarone, ascorbic acid
Drug
Lead sponsor
MaineHealth
Other
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 6, 2026, 9:42 PM EDT
Recruiting Phase 2 Interventional

Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking

NCT07214207
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Suvorexant 10 mg, Placebo
Drug · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 4 Interventional Results available

A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

NCT03257358
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Fingolimod
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
66
States / cities
Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

NCT00054327
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
busulfan, cyclophosphamide, cytarabine, radiation therapy, Etoposide, Stem Cell Transfusion
Drug · Radiation · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 55 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

NCT02141854
View directory record Official record
Conditions
Asthma
Interventions
FS MDPI, Fp MDPI, Placebo MDPI, Albuterol/salmeterol HFA MDI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
85
States / cities
Birmingham, Alabama • Little Rock, Alaska • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 6, 2026, 9:42 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Controlling Hyperadrenergic Activity in Neurologic Injury

NCT01343329
View directory record Official record
Conditions
Traumatic Brain Injury, Dysautonomia
Interventions
Esmolol, Propranolol
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 6, 2026, 9:42 PM EDT
Active, not recruiting No phase listed Observational

Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment

NCT05926024
View directory record Official record
Conditions
Breast Cancer
Interventions
Exercise Recall Patient Reported Outcomes, Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes, Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes, Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a), Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12), Patient Reported Outcomes PROMIS, Patient Reported Outcomes FACT-Endocrine Symptoms, Patient Reported Outcomes Penn Arthralgia Aging Survey, Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE), p16 tumor suppressor gene
Behavioral · Diagnostic Test
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study of Virtually Supervised Mouth Rinses and Flossing

NCT05600231
View directory record Official record
Conditions
Healthy
Interventions
LISTERINE COOL MINT Antiseptic Mouthwash, LISTERINE COOL MINT ZERO Alcohol Mouthwash, Reach Unflavored Waxed Dental Floss, Colgate Cavity Protection Toothpaste
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 6, 2026, 9:42 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Surgical Weight Loss and Alcohol Perception

NCT04299373
View directory record Official record
Conditions
Bariatric Surgery Candidate
Interventions
Alcohol: Oral administration, Alcohol: Intravenous administration
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
30 Years to 55 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 6, 2026, 9:42 PM EDT
Terminated Phase 3 Interventional Results available

A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

NCT04252586
View directory record Official record
Conditions
Rett Syndrome, RTT
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
14
States / cities
Birmingham, Alabama • La Jolla, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 6, 2026, 9:42 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Cannabidiol in Sanfilippo Syndrome

NCT06333041
View directory record Official record
Conditions
Sanfilippo Syndrome, Mucopolysaccharidosis III
Interventions
Epidiolex, Placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
4 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 6, 2026, 9:42 PM EDT
Recruiting Phase 3 Interventional

Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome

NCT05432466
View directory record Official record
Conditions
Vascular Ehlers-Danlos Syndrome
Interventions
ACER-002 (celiprolol) 200 mg BID, Placebo BID
Drug
Lead sponsor
Acer Therapeutics Inc.
Industry
Eligibility
15 Years to 64 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 6, 2026, 9:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Neuroendocrine Response to Oral Alcohol Administration

NCT03165942
View directory record Official record
Conditions
Alcohol Abuse
Interventions
Alcoholic Beverage, Non-Alcoholic Beverage, Ethanol
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 6, 2026, 9:42 PM EDT
Terminated Phase 2 Interventional Results available

Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.

NCT05579769
View directory record Official record
Conditions
Hematologic Malignancy, Myeloid Malignancy
Interventions
Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG), Cyclosporine, Cyclophosphamide, Fludarabine, Methotrexate, Total Body Irradiation (radiation treatment), Bone marrow infusion, Busulfan, Thiotepa
Drug · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 6, 2026, 9:42 PM EDT